Hasten Biopharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 2020-09-16
- Employees
- -
- Market Cap
- -
- Website
- https://www.hastenpharma.com
Clinical Trials
3
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 3
1 (50.0%)A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
Phase 3
Recruiting
- Conditions
- HypercholesterolemiaHyperlipidemia; MixedASCVDDyslipidemiasMetabolic DiseaseHeterozygous Familial HypercholesterolemiaPrimary Hypercholesterolemia
- Interventions
- Drug: matching placebo
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Hasten Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 210
- Registration Number
- NCT06568471
- Locations
- 🇨🇳
Beijing Anzhen Hospital of Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing Luhe Hospital, Capital Medical Univeristy, Beijing, Beijing, China
🇨🇳Beijing Tsinghua Changgeng Hospital, Beijing, Beijing, China
A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Hasten Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06504043
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study
Recruiting
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Hasten Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 1215
- Registration Number
- NCT05947448
- Locations
- 🇨🇳
Junbo Ge, Shanghai, Shanghai, China
News
AI-Powered HASTEN Tool Accelerates Virtual Drug Screening 10-Fold
Finnish researchers have developed an ML-powered tool called HASTEN that reduces virtual drug screening time from 6 months to under 10 days for 1.56 billion molecules.